In silico study of phytochemicals contained in Brucea javanica in inhibiting the InhA enzyme as antituberculosis
https://doi.org/10.4081/jphia.2023.2518
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background: Currently Mycobacterium tuberculosis is found to be resistant to the treatment of tuberculosis with rifampin and isoniazid (INH) and often stated as multi-drug resistance (MDR). Knowledge and determination of biological properties of plant extracts is a source of drug candidates in various health fields. Therefore, natural products are important in the discovery of new drugs, especially in disease therapy, particularly for tropical dis- eases, tuberculosis. Brucea javanica, known as Buah Makasar, is found in many Asian countries including Indonesia. This plant fruit has a very bitter taste so it cannot be directly consumed and is often used as a traditional medicine to prevent some diseases, especially malaria. There has been no research on the effectiveness of Buah Makasar in tuberculosis.
Objective: This study aims to identify compounds contained in Brucea javanica, namely bruceines, bruceosides and yadanzio-sides in inhibiting the InhA enzyme found in the wall of Mycobacterium tuberculosis.
Methods: This in-silico study is using Molegro Virtual Docker (MVD) Ver. 5.5. We compared it to the native ligand, namely N-(4- Methylbenzoyl)-4-Benzylpiperidine (code: 4PI) and the reference drug standard, INH.
Results: In-silico results show that yadanziosides found in Brucea javanica have the potential to inhibit the InhA enzyme. Bruceoside F (-190.76 Kcal/mol) has the lowest MolDock score among the 27 other compounds. It is also having lower MolDock score than the native ligand 4PI (-120.61 Kcal/mol) and INH (- 54.44 Kcal/mol).
Conclusions: Brucea javanica can be considered as source of drug development for againts tuberculosis.
https://www.who.int/health-topics/tuberculosis# accessed in January 2021
https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/infodatin-tuberkulosis-2018.pdf accessed in January 2021
Balachandra B, Radha KS, Jagadeesh B, Tanjore SB, Two decades of TB discovery efforts. What have we learned? Appl Sci 2020;10:5704-9. DOI: https://doi.org/10.3390/app10165704
Jesse WHL, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Sci 2009;325:161-5. DOI: https://doi.org/10.1126/science.1168243
Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016;79:629−61. DOI: https://doi.org/10.1021/acs.jnatprod.5b01055
Salazar MO, Ramallo IA, Micheloni O, et al. Chemically engineered extracts: bioactivity alteration through sulfonylation. Bioorg Med Chem Lett 2009;19:5067-70. DOI: https://doi.org/10.1016/j.bmcl.2009.07.038
Ramallo IA, Salazar MO, Mendez L, Furlan E. Chemically engineered extracts: source of bioactive compounds. Acc Chem Res 2011;44:241-50. DOI: https://doi.org/10.1021/ar100106n
Lopez SN, Ramallo IA, Sierra MG, et al. Chemically engineered extracts as an alternative source of bioactive natural product-like compounds. PNAS 2007;104:441-4. DOI: https://doi.org/10.1073/pnas.0608438104
Retno W, Mangestuti A. Chemical constituents and bioactivities of Several indonesian plants typically uses in jamu. Chem Pharm Bull 2018;66:506-18. DOI: https://doi.org/10.1248/cpb.c17-00983
Henny H, Idha S. Phytochemical tested and in vitro screening anti malaria activity of belilik (Brucea javanica (L)). MERR against Plasmodium falciparum. J Bio Res 2013;19:1-4. DOI: https://doi.org/10.23869/bphjbr.19.1.20131
Qing MY, Liang LB, Shu ZH, et al. Isolation, chemotaxonomic significance and cytotoxic effects of quassinoids from B. javanica. Phytoterapia 2015;105:66-72. DOI: https://doi.org/10.1016/j.fitote.2015.06.004
Joshi SD, Kumar SRP, Patil S, et al. Chemical synthesis, molecular modeling and pharmacophore mapping of new pyrrole derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth. Med Chem Res 2019;28:1838-63. DOI: https://doi.org/10.1007/s00044-019-02418-1
Hari S, Galih SP, Yuniarta TA, Tutuk B. Synthesis and molecular docking studies of N'-benzoylsalicylhydrazide derivatives as antituberculosis through InhA enzyme inhibition. Indonesian J Pharm 2020;29:198–205. DOI: https://doi.org/10.14499/indonesianjpharm29iss4pp198
Zhang J, Xu HX, Dou YX, et al. Major constituents from Brucea javanica and their pharmacological actions. Front Pharmacol 2022. DOI: https://doi.org/10.3389/fphar.2022.853119
Thomsen R, Christensen MH. MolDock: A new technique for high-accuracy molecular docking. J Med Chem 2006;49:3315-21. DOI: https://doi.org/10.1021/jm051197e
Thomas HA. Merck Molecular Force Field. I Basis, form, scope, parametrization, and performance of MMFF94. J Com Chem 1996;17:490-519. DOI: https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
National Center for Biotechnology Information. PubChem Compound Summary for CID 1415427, N-(4-Methylbenzoyl) -4-Benzylpiperidine. 2022.
Prasad MS, Bhole RP, Khedekar PB, Chikhale RV. Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery. Bioorganic Chemistry 2021;115:105242. DOI: https://doi.org/10.1016/j.bioorg.2021.105242
Xin H, Akram A, Paul ROM. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase by InhA arylamides. BMC 2007;15:6649-58. DOI: https://doi.org/10.1016/j.bmc.2007.08.013
Copyright (c) 2023 the Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Downloads
Citations
